Pfizer Inc. (NYSE:PFE) is scheduled to report third-quarter earnings on November 4th, with analysts projecting a decline in EPS to $0.64 and revenue to $16.52 billion, down from $1.06 and $17.7 billion respectively year-over-year. Concurrently, Pfizer has filed a lawsuit against Metsera, Inc. and Novo Nordisk, alleging breach of contract and tortious interference related to Metsera's merger agreement with Pfizer. Shares of Pfizer saw a marginal increase, closing at $24.66 on Monday.
Pfizer (NYSE:PFE) is poised to report a challenging third quarter, with analysts forecasting a significant year-over-year decline in key financial metrics. Consensus estimates project quarterly earnings at $0.64 per share, down from $1.06, and revenue at $16.52 billion, a decrease from $17.7 billion in the prior year period. These projections signal fundamental headwinds for the healthcare giant. Adding to the complexity, Pfizer has initiated a lawsuit against Metsera, Inc. and Novo Nordisk, alleging breach of contract and tortious interference related to Metsera's merger agreement obligations. This legal action introduces M&A uncertainty and potential financial liabilities or strategic disruptions for all parties involved, reflected in the mildly negative sentiment for PFE and more negative sentiment for MTSR and NVO. Analyst sentiment remains largely cautious, with several firms maintaining Neutral or Equal-Weight ratings. While some analysts, like B of A Securities and Citigroup, recently increased price targets, others, such as Morgan Stanley, have reduced theirs, indicating a mixed but generally non-bullish outlook. PFE shares saw only a marginal 0.04% increase to $24.66 on Monday, suggesting a muted market reaction ahead of the earnings call.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
